AstraZeneca Lowers Vaccine Efficacy

The transcript discusses the slight differences in vaccine efficacy rates and the actions of the DSMB, which are seen as unnecessary. It highlights the potential impact on AstraZeneca's public perception and FDA approval, despite the solid trial data. The conversation also touches on the EU-UK vaccine export scenario, emphasizing the need for political neutrality to allow scientific progress.

What did the speaker suggest about the relationship between the EU and the UK regarding vaccine exports?

What was the speaker's wish regarding the involvement of politicians in vaccine distribution?